No Data
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $5
BofA Securities analyst Allen Lutz maintains $GoodRx(GDRX.US)$ with a sell rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 53.0% and a
GoodRx Holdings Underperform Rating: Concerns Over Biosimilar Affordability and Generic Reimbursement Market Dynamics
GoodRx Partners With Boehringer Ingelheim to Discount Humira Biosimilar
Express News | GoodRx: Offering Prices for Both Formulations of Adalimumab-Adbm as Pre-Filled Syringe or Autoinjector at $550 per Two-Pack
Express News | GoodRx: Initiative to Provide Citrate-Free Adalimumab-Adbm, Boehringer’s Biosimilar to Humira, at Low Cash Price Exclusively on GoodRx
GoodRx's Monthly Active Consumers Likely to Be Q2 Results Focus, RBC Says
GoodRx Holdings' (GDRX) monthly active consumers growth will likely be the focus in Q2 results, RBC Capital Markets said in an earnings preview Wednesday.Monthly active consumers, or MAC, remains